ACST Stock – (NASDAQ: ACST) is providing an update on the usage

ACST Stock – (NASDAQ: ACST) is giving an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is providing an update on the use of the “at-the market” equity of its providing program.

As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to carry out a “at the market” equity offering program under which Acasti may issue and market from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares were sold at prevailing market rates averaging US$1.0747 a share. No securities were sold through the facilities of the TSXV or, to the understanding of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March five, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and can supply the Company with additional freedom in its ongoing review process to enjoy as well as evaluate strategic alternatives.

Approximately Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription drugs making use of OM3 fatty acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical proof of efficacy as well as safety in lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for clients with serious HTG.

Forward Looking Statements – ACST Stock

Statements in that press release which aren’t statements of historical or current truth constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking assertions involve known and unknown risks, uncertainties, and other unknown factors that could cause the particular outcomes of Acasti to be materially different from historical success or from any later results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, readers are urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward looking statements, which speak just as of the date of this press release. Forward-looking claims in that press release include, but are not restricted to, info or statements concerning Acasti’s strategy, succeeding operations and the review of its of strategic options.

The forward looking assertions contained in this specific press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” area in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor section of Acasti’s website at www.acastipharma.com. All forward looking assertions in this press release are available as of the particular date of this press release.

ACST Stock – Acasti doesn’t undertake to upgrade any such forward looking statements whether as a consequence of info which is new, future events or even otherwise, except as required by law. The forward looking assertions contained herein are also subject generally to risks and assumptions as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is giving an update on the usage